Citations

Clear

74 citation(s) found for "Huang, Haojie".

The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells
Ji, Lu , Lonergan, Peter E. , Nacusi, Lucas P., Wang, Liguo , Schmidt, Lucy J., Sun, Zhifu , Steen, Travis Van der, Boorjian, Stephen A. , Kosari, Farhad , Vasmatzis, George , Klee, George G., Wang, Chunxi , Tindall, Donald J., Lu, Ji, van der Steen, Travis, Balk, Steven P. , Huang, Haojie , Sun, Zhifu , Wang, Liguo

Mayo Clinic

Journal of Urology | August 14, 2014 | Volume: 193 | Issue: 2 | Pages: 690-698

10.1016/j.juro.2014.08.043 | PMID 25132238 Get It

Destruction of DDIT3/CHOP Protein by Wild-Type SPOP but Not Prostate Cancer-Associated Mutants
Zhang, Pingzhao , Gao, Kun , Tang, Yan , Jin, Xiaofeng , Yu, Hongxiu , Wang, Huan , Zhang, Yuanyuan , Wang, Dejie , Yu, Long , Jian, An , Huang, Haojie , Wang, Chenji

Mayo Clinic

Human Mutation | July 2, 2014 | Volume: 35 | Issue: 9 | Pages: 1142-1151

10.1002/humu.22614 | PMID 24990631 Get It

CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy
Ding, Liya , Pan, Yunqian , Zhong, Jian , Regan, Kevin M., Wang, Liguo , Yu, Chunrong, Rizzardi, Anthony E., Zhang, Jun , Schmechel, Stephen C. , Cheville, John C. , Deursen, Jan van, Tindall, Donald J., Cheng, Liang , Chen, Daiwen , Liu, Ping , Cheng, Liang , Huang, Haojie , Wang, Liguo , Cheng, Liang

Mayo Clinic

Cancer Research | February 3, 2014 | Volume: 74 | Issue: 7 | Pages: 2050-2061

10.1158/0008-5472.can-13-1659 | PMID 24491799 Get It

Abstract Despite the high incidence and mortality of prostate cancer, the etiology of this disease is not fully understood. In this study, we develop functional evidence for CBP and PTEN interaction in prostate cancer based on findings of their correlate expression in the human disease. Cbppc−/−;Ptenpc+/− mice exhibited higher cell proliferation in the prostate and an early onset of high-grade prostatic intraepithelial neoplasia. Levels of EZH2 methyltransferase were increased along with its Thr350 phosphorylation in both mouse Cbp−/−; Pten+/− and human prostate cancer cells. CBP loss and PTEN deficiency cooperated to trigger a switch from K27-acetylated histone H3 to K27-trimethylated bulk histones in a manner associated with decreased expression of the growth inhibitory EZH2 target genes DAB2IP, p27KIP1, and p21CIP1. Conversely, treatment with the histone deacetylase inhibitor panobinostat reversed this switch, in a manner associated with tumor suppression in Cbppc−/−;Ptenpc+/− mice. Our findings show how CBP and PTEN interact to mediate tumor suppression in the prostate, establishing a central role for histone modification in the etiology of prostate cancer and providing a rationale for clinical evaluation of epigenetic-targeted therapy in patients with prostate cancer. Cancer Res; 74(7); 2050–61. ©2014 AACR.
p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis
Zhong, Jian , Ding, Liya , Bohrer, Laura R., Pan, Yunqian , Liu, Ping , Sebo, Thomas J., Karnes, R. Jeffrey , Tindall, Donald J., Deursen, Jan van, van Deursen, Jan, Zhang, Jun , Huang, Haojie

Mayo Clinic

Cancer Research | January 30, 2014 | Volume: 74 | Issue: 6 | Pages: 1870-1880

10.1158/0008-5472.can-13-2485 | PMID 24480624 Get It

Abstract Overexpression of the histone acetyltransferase p300 is implicated in the proliferation and progression of prostate cancer, but evidence of a causal role is lacking. In this study, we provide genetic evidence that this generic transcriptional coactivator functions as a positive modifier of prostate tumorigenesis. In a mouse model of PTEN deletion–induced prostate cancer, genetic ablation of p300 attenuated expression of the androgen receptor (AR). This finding was confirmed in human prostate cancer cells in which PTEN expression was abolished by RNA interference–mediated attenuation. These results were consistent with clinical evidence that the expression of p300 and AR correlates positively in human prostate cancer specimens. Mechanistically, PTEN inactivation increased AR phosphorylation at serine 81 (Ser81) to promote p300 binding and acetylation of AR, thereby precluding its polyubiquitination and degradation. In support of these findings, in PTEN-deficient prostate cancer in the mouse, we found that p300 was crucial for AR target gene expression. Taken together, our work identifies p300 as a molecular determinant of AR degradation and highlights p300 as a candidate target to manage prostate cancer, especially in cases marked by PTEN loss. Cancer Res; 74(6); 1870–80. ©2014 AACR.
Abstract A31: Targeting Oncogenic Ras Activation for Cancer Prevention
Ji, Baoan , Haojie, Huang, Liu, Yan , Craig, Logsdon, Haojie, Huang, Daniluk, Jarosław

Mayo Clinic

Cancer Prevention Research | January 23, 2014 | Volume: 5 | Issue: 11_Supplement | Pages: A31-A31

10.1158/1940-6207.prev-12-a31 Get It

Abstract Increased Ras activity levels due to active mutations of Ras are critical for tumorigenesis. These oncogenic Ras mutations are considered to be locked in a permanent “On” state and “constitutively active”. Yet, surprisingly, expression of oncogenic Ras at physiologically levels in genetically engineered mice with “knock-in” mutant Ras has little effect on most cells. Here, we demonstrated that oncogenic K-Ras is not at all constitutively active. Rather, oncogenic K-Ras can be readily activated by upstream stimulants such as diet-induced hormones (eg. Cholecystokinin) and inflammatory stimuli (eg. PGE2 or LPS). However, unlike wild-type Ras, oncogenic K-Ras is very slow to inactivate. This effect on oncogenic K-Ras signaling kinetics leads to dramatically amplified levels of Ras activity initiated by physiologic stimuli. Sustained increase of Ras activity involves a feed-forward loop in which increased Ras activity generates more inflammatory mediators which act as Ras stimulants. High Ras activity led to acinar cell senescence and generated inflammation and fibrosis resembling the histological features of chronic inflammation with abundant precancerous lesions that spontaneously progressed to cancer only in animals expressing physiologic levels of oncogenic Ras. In summary, oncogenic Ras is not constitutively active but predisposes cells to pathological alterations dependent upon Ras activity levels. Since a large population of normal healthy humans harbors Ras mutations, in addition to targeting Ras downstream signaling pathways a reduction of factors that can activate Ras signaling may provide an important alternative cancer preventive value. These data also provide a mechanistic explanation for the link between inflammation, Ras and cancer and provide insights for cancer prevention. Citation Format: Ji Baoan, Huang Haojie, Liu Yan, Daniluk Jaroslaw, Logsdon Craig. Targeting oncogenic Ras activation for cancer prevention. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A31.
CrossMap: a versatile tool for coordinate conversion between genome assemblies
Zhao, Hao , Sun, Zhifu , Kocher, Jean‐Pierre , Wang, Liguo , Wang, Jing , Huang, Haojie , Sun, Zhifu , Wang, Liguo

Mayo Clinic

Bioinformatics | December 19, 2013 | Volume: 30 | Issue: 7 | Pages: 1006-1007

10.1093/bioinformatics/btt730 | PMID 24351709 Get It

Abstract Motivation: Reference genome assemblies are subject to change and refinement from time to time. Generally, researchers need to convert the results that have been analyzed according to old assemblies to newer versions, or vice versa, to facilitate meta-analysis, direct comparison, data integration and visualization. Several useful conversion tools can convert genome interval files in browser extensible data or general feature format, but none have the functionality to convert files in sequence alignment map or BigWig format. This is a significant gap in computational genomics tools, as these formats are the ones most widely used for representing high-throughput sequencing data, such as RNA-seq, chromatin immunoprecipitation sequencing, DNA-seq, etc. Results: Here we developed CrossMap, a versatile and efficient tool for converting genome coordinates between assemblies. CrossMap supports most of the commonly used file formats, including BAM, sequence alignment map, Wiggle, BigWig, browser extensible data, general feature format, gene transfer format and variant call format. Availability and implementation: CrossMap is written in Python and C. Source code and a comprehensive user’s manual are freely available at: http://crossmap.sourceforge.net/. Contact: Kocher.JeanPierre@mayo.edu or wang.liguo@mayo.edu Supplementary information: Supplementary data are available at Bioinformatics online.
Posttranslational Modification of the Androgen Receptor in Prostate Cancer
Steen, Travis Van der, Tindall, Donald J., van der Steen, Travis, Huang, Haojie

Mayo Clinic

International Journal of Molecular Sciences | July 17, 2013 | Volume: 14 | Issue: 7 | Pages: 14833-14859

10.3390/ijms140714833 | PMID 23863692 Get It

The androgen receptor (AR) is important in the development of the prostate by regulating transcription, cellular proliferation, and apoptosis. AR undergoes posttranslational modifications that alter its transcription activity, translocation to the nucleus and stability. The posttranslational modifications that regulate these events are of utmost importance to understand the functional role of AR and its activity. The majority of these modifications occur in the activation function-1 (AF1) region of the AR, which contains the transcriptional activation unit 1 (TAU1) and 5 (TAU5). Identification of the modifications that occur to these regions may increase our understanding of AR activation in prostate cancer and the role of AR in the progression from androgen-dependent to castration-resistant prostate cancer (CRPC). Most of the posttranslational modifications identified to date have been determined using the full-length AR in androgen dependent cells. Further investigations into the role of posttranslational modifications in androgen-independent activation of full-length AR and constitutively active splicing variants are warranted, findings from which may provide new therapeutic options for CRPC.
Abstract LB-425: An NF-κB pathway mediated positive feedback loop amplifies Ras activity to pathological levels in mice
Ji, Baoan , Daniluk, Jarosław , Liu, Yan , Deng, Defeng , Logsdon, Craig D. , Huang, Haojie , Wang, Huamin

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: LB-425-LB-425

10.1158/1538-7445.am2012-lb-425 Get It

Abstract Elevated Ras activity is critical for Ras induced tumorigenesis. However, the underlying mechanisms that lead to pathological levels of Ras activity are unclear. Here, we found that stimulation of Ras signaling by typical inflammatory stimuli was transient and had no long term sequelae in wild-type mice. In contrast, these stimuli generated prolonged Ras signaling and led to chronic inflammation and precancerous lesions (PanINs) in mice expressing endogenous levels of oncogenic K-Ras. The effects of inflammatory stimuli on oncogenic Ras expressing mice were disrupted by deleting IKK2 or inhibiting Cox-2. Likewise, the expression of active IKK2 or Cox-2, or treatments with LPS generated chronic inflammation and PanINs only in mice expressing oncogenic Ras. The data support that in the presence of oncogenic Ras, inflammatory stimuli trigger an NF-κB mediated positive feedback mechanism involving Cox-2 that amplifies Ras activity to pathological levels. Because a large portion of the adult human population possesses Ras mutations in tissues including colon, pancreas, and lung, disruption of this positive feedback loop may be an important strategy for cancer prevention. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-425. doi:1538-7445.AM2012-LB-425
FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion
Zhang, Haijun , Pan, Yunqian , Choe, Chungyoul , Lindgren, Bruce R. , Jensen, Eric D. , Westendorf, Jennifer J., Cheng, Liang , Zheng, Li Wu , Huang, Haojie , Cheng, Liang

Mayo Clinic

Cancer Research | April 20, 2011 | Volume: 71 | Issue: 9 | Pages: 3257-3267

10.1158/0008-5472.can-10-2603 | PMID 21505104 Get It

Abstract Prostate cancer patients with regional lymph node involvement at radical prostatectomy often experience disease progression to other organs, with the bone as the predominant site. The transcription factor Runx2 plays an important role in bone formation and prostate cancer cell migration, invasion, and metastasis. Here we showed that the forkhead box O (FOXO1) protein, a key downstream effector of the tumor suppressor PTEN, inhibits the transcriptional activity of Runx2 in prostate cancer cells. This inhibition was enhanced by PTEN but diminished by active Akt. FOXO1 bound to Runx2 in vitro and in vivo and suppressed Runx2's activity independent of its transcriptional function. FOXO1 inhibited Runx2-promoted migration of prostate cancer cells, whereas silencing of endogenous FOXO1 enhanced prostate cancer cell migration in a Runx2-dependent manner. Forced expression of FOXO1 also inhibited Runx2-promoted prostate cancer cell invasion. Finally, we found that expression of PTEN and the level of FOXO1 in the nucleus is inversely correlated with expression of Runx2 in a cohort of prostate cancer specimens from patients with lymph node and bone metastasis. These data reveal FOXO1 as a critical negative regulator of Runx2 in prostate cancer cells. Inactivation of FOXO1 due to frequent loss of PTEN in prostate cancer cells may leave the oncogenic activities of Runx2 unchecked, thereby driving promiscuous expression of Runx2 target genes involved in cell migration and invasion and favoring prostate cancer progression. Cancer Res; 71(9); 3257–67. ©2011 AACR.
Reduced Tumor Necrosis Factor Receptor–Associated Death Domain Expression Is Associated with Prostate Cancer Progression
Wang, Diping, Montgomery, Bruce , Schmidt, Lucy J., Nelson, Peter S. , Tindall, Donald J., Mostaghel, Elahe A. , Huang, Haojie

Mayo Clinic

Cancer Research | November 24, 2009 | Volume: 69 | Issue: 24 | Pages: 9448-9456

10.1158/0008-5472.can-09-1903 | PMID 19934328 Get It

Abstract By using LNCaP and its derivative cell lines, we first observed an association between tumor necrosis factor-α (TNF-α) resistance and hormone independence. Moreover, we found that the expression of tumor necrosis factor receptor–associated death domain (TRADD) was reduced in androgen deprivation–independent cells compared with that in androgen deprivation–dependent cells. TRADD is a crucial transducer for TNF-α–induced nuclear factor-κB (NF-κB) activation. Knocking down TRADD expression in LNCaP cells impaired TNF-α–induced NF-κB activation and androgen receptor repression, whereas overexpression of TRADD in C4-2B cells restored their sensitivity to TNF-α. Finally, we found that androgen deprivation reduces TRADD expression in vitro and in vivo, suggesting that androgen deprivation therapy may promote the development of TNF-α resistance by reducing TRADD expression during prostate cancer progression. [Cancer Res 2009;69(24):9448–56]